CORONA Remedies Limited has announced the acquisition of the antiseptic brand Wokadine® from Dr. Reddy’s Laboratories Ltd., marking its fifth brand acquisition and a significant step in strengthening its presence in the Indian pharmaceutical market. The move signals CORONA Remedies’ entry into the ₹648 crore Povidone Iodine segment, where Wokadine® holds the second-largest share by value.
The acquisition, effective immediately, is fully funded through internal accruals and cash. With a 46-year legacy of clinical trust and protection, Wokadine® is widely used by surgeons, ENT specialists, general physicians, and gynaecologists. The brand’s 14 stock keeping units (SKUs) cover diverse clinical applications, supporting treatment across hospitals and community settings.
“By building on our strong relationships with healthcare professionals, we aim to deepen market penetration and are confident in accelerating the growth of this brand,” said Tejas Kothari, Vice President, Corporate Strategy & Business Development, CORONA Remedies. He emphasized that the company continues to evaluate both organic and inorganic growth opportunities, leveraging its pan-India presence and credibility among the medical fraternity.
CORONA Remedies intends to use its extensive sales and distribution network to improve access to Wokadine® across metro, semi-metro, urban, semi-urban, and rural markets. The company said this strategic acquisition aligns with its mission of advancing “Healing” through integrated healthcare solutions and reinforces its growing equity among key specialities.
Founded in 2004, CORONA Remedies is an India-focused branded pharmaceutical company engaged in developing, manufacturing, and marketing formulations across core therapeutic areas including women’s health, cardio-diabetes, pain management, and urology. The company operates WHO-GMP and EU-GMP certified facilities and maintains two DSIR-approved R&D centres employing more than 100 scientists. With over 5,000 employees, CORONA Remedies has steadily expanded its footprint in the domestic market through a blend of product innovation and targeted brand acquisitions.
Industry analysts view the acquisition as a calculated step to consolidate CORONA’s therapeutic portfolio and tap new growth opportunities in the antiseptic and wound care market, which continues to show steady demand across both institutional and retail segments.
